Citi analyst Samantha Semenkow has maintained their bullish stance on TSVT stock, giving a Buy rating on November 14.
Samantha Semenkow has given her Buy rating to 2seventy bio due to a combination of factors. The primary reason being the anticipated revenue growth of Abecma in 2024, which is expected to be driven by label expansion to 3L+ MM in the coming month. Despite acknowledging the near-term uncertainty surrounding Abecma’s commercial performance, Semenkow maintains a positive outlook.
Her positive rating also takes into account the management’s commentaries suggesting a lack of anticipation for a large influx of earlier-line patients for Abecma immediately post-approval. Hence, Semenkow has refined her 3L+ MM forecasts to reflect a more gradual launch in 2024. Even though these changes have resulted in a lower target price to $9 per share (a reduction of $2), she maintains her Buy/High Risk rating, indicating a strong belief in the company’s potential for future growth.
According to TipRanks, Semenkow is an analyst with an average return of -11.6% and a 40.00% success rate. Semenkow covers the Healthcare sector, focusing on stocks such as Beam Therapeutics, Sana Biotechnology, and 2seventy bio.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
2seventy bio (TSVT) Company Description:
2seventy bio Inc is primarely in the business of pharmaceutical preparations.
Read More on TSVT:
